Vol.
30
No.
18
April 30, 2004Apr 30, 2004
Free

Research teams link response to Iressa to mutations in EGF receptor.

SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

NCI blocked groups from phase III Iressa studies.

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.

Funding opportunities listed.

April issue of Business & Regulatory Report included (8 additional pages).

Login